- Home
- XPON vs PRPO Comparison
XPON vs PRPO Comparison
Compare XPON & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- PRPO
- Stock Information
- Founded
- XPON 2016
- PRPO N/A
- Country
- XPON United States
- PRPO United States
- Employees
- XPON N/A
- PRPO 57
- Industry
- XPON Electronic Components
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- XPON Technology
- PRPO Industrials
- Exchange
- XPON Nasdaq
- PRPO Nasdaq
- Market Cap
- XPON 1.8M
- PRPO 9.5M
- IPO Year
- XPON 2022
- PRPO N/A
- Fundamental
- Price
- XPON $3.27
- PRPO $6.59
- Analyst Decision
- XPON
- PRPO
- Analyst Count
- XPON 0
- PRPO 0
- Target Price
- XPON N/A
- PRPO N/A
- AVG Volume (30 Days)
- XPON 3.1M
- PRPO 7.9K
- Earning Date
- XPON 11-07-2024
- PRPO 11-11-2024
- Dividend Yield
- XPON N/A
- PRPO N/A
- EPS Growth
- XPON N/A
- PRPO N/A
- EPS
- XPON N/A
- PRPO N/A
- Revenue
- XPON $4,998,801.00
- PRPO $16,719,999.00
- Revenue This Year
- XPON $0.68
- PRPO $75.18
- Revenue Next Year
- XPON $29.04
- PRPO N/A
- P/E Ratio
- XPON N/A
- PRPO N/A
- Revenue Growth
- XPON N/A
- PRPO 52.61
- 52 Week Low
- XPON $2.09
- PRPO $4.31
- 52 Week High
- XPON $639.00
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- XPON 37.66
- PRPO 52.82
- Support Level
- XPON $2.70
- PRPO $6.42
- Resistance Level
- XPON $4.29
- PRPO $6.99
- Average True Range (ATR)
- XPON 0.77
- PRPO 0.33
- MACD
- XPON 0.50
- PRPO -0.04
- Stochastic Oscillator
- XPON 33.62
- PRPO 69.91
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.